{"doc_id": "med:pmid:26637405", "sentence_id": "med:pmid:26637405:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the present review, we have summarized the current knowledge on the NP system, focusing on its role in HF and we provide an overview of the pharmacological attempts to modulate NP in HF: from the negative results of the study with neprilysin (NEP) inhibitors, alone or associated with an ACE inhibitor and vasopeptidase inhibitors, to the most recently and extremely encouraging results obtained with the new pharmacological class of Ang receptor and NEP inhibitor, currently defined ARNI (Ang receptor NEP inhibitor).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26754626", "sentence_id": "med:pmid:26754626:sec:conclusion:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The benefit of LCZ696 (sacubitril/valsartan) compared with enalapril was consistent across the range of HbA1c in the trial. In patients with heart failure and reduced ejection fraction, dysglycemia is common and pre-diabetes mellitus is associated with a higher risk of adverse cardiovascular outcomes (compared with patients with no diabetes mellitus and HbA1c < 6.0%).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26754626", "sentence_id": "med:pmid:26754626:sec:results:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We investigated these in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. We examined clinical outcomes in 8399 patients with heart failure and reduced ejection fraction according to history of diabetes mellitus and glycemic status (baseline hemoglobin A1c [HbA1c]: < 6.0% [< 42 mmol/mol], 6.0%-6.4% [42-47 mmol/mol; pre-diabetes mellitus], and \u2265 6.5% [\u2265 48 mmol/mol; diabetes mellitus]), in Cox regression models adjusted for known predictors of poor outcome.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26754626", "sentence_id": "med:pmid:26754626:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26873036", "sentence_id": "med:pmid:26873036:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PARADIGM-HF trial has proved the superiority of sacubitril/valsartan (LCZ696) over ACE inhibitor enalapril to reduce mortality and morbidity of symptomatic HF patients with reduced ejection fraction (HFrEF), setting the grounds for the replacement of ACE inhibitors by sacubitril/valsartan in the management of HFrEF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26873495", "sentence_id": "med:pmid:26873495:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the large, randomized, double-blind, PARADIGM-HF trial, sacubitril/valsartan reduced the incidence of death from cardiovascular causes or first hospitalization for worsening heart failure (composite primary endpoint) significantly more than the angiotensin converting enzyme (ACE) inhibitor enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26873495", "sentence_id": "med:pmid:26873495:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan was also superior to enalapril in reducing death from any cause and in limiting the progression of heart failure.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26873495", "sentence_id": "med:pmid:26873495:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Symptomatic hypotension was significantly more common with sacubitril/valsartan than with enalapril; the incidence of angio-oedema was low.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26873495", "sentence_id": "med:pmid:26873495:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Therefore, sacubitril/valsartan is a more effective replacement for an ACE inhibitor or an ARB in the treatment of HFrEF, and is likely to influence the basic approach to treatment.", "sentiment_label": "NEU", "sentiment_score": 0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26915374", "sentence_id": "med:pmid:26915374:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with enalapril in patients with heart failure (HF) and reduced ejection fraction (EF) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26915374", "sentence_id": "med:pmid:26915374:sec:results:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We evaluated the influence of EF on clinical outcomes and on the effectiveness of sacubitril/valsartan compared with enalapril. Eight thousand three hundred ninety-nine patients with New York Heart Association class II to IV HF with reduced EF [left ventricular EF (LVEF) \u226440%] were randomized to sacubitril/valsartan 97/103 mg twice daily versus enalapril 10 mg twice daily and followed for a median of 27 months.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26915374", "sentence_id": "med:pmid:26915374:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26976916", "sentence_id": "med:pmid:26976916:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, valsartan/sacubitril significantly reduced mortality and hospitalization for heart failure, as well as blood pressure, compared with enalapril in patients with heart failure, reduced ejection fraction, and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriuretic peptide.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:26992459", "sentence_id": "med:pmid:26992459:sec:methods:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "When compared to ACE inhibitor therapy in systolic heart failure patients, sacubitril/valsartan demonstrated reductions in all-cause mortality and hospitalization due to heart failure while maintaining a similar safety profile.<h4>What is new and conclusion</h4>A formulation that contains both sacubitril and valsartan was manufactured and approved by the FDA in July 2015 for the reduction of mortality and hospitalization in systolic heart failure patients.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27092662", "sentence_id": "med:pmid:27092662:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "With the published results of the landmark trial Prospective comparison of ARNI with ACEI to Determine the Impact on Global Mortality and morbidity in HF (PARADIGM-HF), a new direction in the treatment of HF is anticipated.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27143684", "sentence_id": "med:pmid:27143684:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The benefit of sacubitril/valsartan over enalapril was similar to the primary outcome for the expanded composite (hazard ratio, 0.79; 95% confidence interval, 0.73-0.86) and was consistent across the components of the latter. Focusing only on HF hospitalizations underestimates the frequency of worsening and the serious implications of all manifestations of worsening.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27143684", "sentence_id": "med:pmid:27143684:sec:results:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We studied the frequency and prognostic importance of these episodes of worsening in the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Outpatient intensification of HF therapy was added to an expanded composite outcome with ED visits, HF hospitalizations, and cardiovascular deaths.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27143684", "sentence_id": "med:pmid:27143684:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).", "sentiment_label": "NEG", "sentiment_score": -3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27170530", "sentence_id": "med:pmid:27170530:sec:conclusion:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Rates by ACEI/ARB pre-study dose stratification were 82.6% vs. 83.8% (P = 0.783) for high-dose/'condensed' vs. high-dose/'conservative' and 84.9% vs. 73.6% (P = 0.030) for low-dose/'conservative' vs. low-dose/'condensed'. Initiation/uptitration of sacubitril/valsartan from 50 to 200 mg twice daily over 3 or 6 weeks had a tolerability profile in line with other HF treatments.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27207980", "sentence_id": "med:pmid:27207980:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After initial failures with neprilysin inhibition alone or dual neprilysin-angiotensin converting enzyme (ACE) inhibition, the Prospective comparison of angiotensin receptor neprilysin inhibitor (ARNI) with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) trial demonstrated that morbidity and mortality can be improved with the angiotensin receptor blocker neprilysin inhibitor sacubitril/valsartan (formerly LCZ696).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27207980", "sentence_id": "med:pmid:27207980:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In comparison to the ACE inhibitor enalapril, sacubitril/valsartan reduced the occurrence of the primary end point (cardiovascular death or hospitalisation for HF) by 20% with a 16% reduction in all-cause mortality.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27207980", "sentence_id": "med:pmid:27207980:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "These findings suggest that sacubitril/valsartan should replace an ACE inhibitor or angiotensin receptor blocker as the foundation of treatment of symptomatic patients (NYHA II-IV) with HF and a reduced ejection fraction.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27283779", "sentence_id": "med:pmid:27283779:sec:conclusion:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, the treatment benefit of sacubitril/valsartan over enalapril following a dose reduction was similar (HR 0.80, 95% CI 0.70-0.93, P < 0.001) to that observed in patients who had not experienced any dose reduction (HR 0.79, 95% CI 0.71-0.88, P < 0.001). In PARADIGM-HF, study medication dose reduction identified patients at higher risk of a major cardiovascular event.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27283779", "sentence_id": "med:pmid:27283779:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The magnitude of benefit for patients on lower doses of sacubitril/valsartan relative to those on lower doses of enalapril was similar to that of patients who remained on target doses of both drugs.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27283779", "sentence_id": "med:pmid:27283779:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril.<h4>Methods and results</h4>In a post-hoc analysis from PARADIGM-HF, we characterized patients by whether they received the maximal dose (200 mg sacubitril/valsartan or 10 mg enalapril twice daily) throughout the trial or had any dose reduction to lower doses (100/50/0 mg sacubitril/valsartan or 5/2.5/0 mg enalapril twice daily).", "sentiment_label": "POS", "sentiment_score": 3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27283779", "sentence_id": "med:pmid:27283779:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27296397", "sentence_id": "med:pmid:27296397:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The 8442 patients randomized in the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, in which sacubitril/valsartan (LCZ696) reduced both death and HF hospitalization more than enalapril, were a subset of 10\u2009521 patients entering sequential, single-blind run-in periods (enalapril 10 mg twice daily for 2 weeks followed by LCZ696 200 mg twice daily for 4 to 6 weeks) to ensure short-term tolerability of the 2 study medications.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27334058", "sentence_id": "med:pmid:27334058:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A recent clinical study indicated that an angiotensin II (Ang II) type 1 (AT<sub>1</sub>) receptor-neprilysin inhibitor (ARNi) designated LCZ696 (sacubitril/valsartan, as combined sodium complex) was superior to enalapril at reducing the risks of death and hospitalization due to heart failure.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27395349", "sentence_id": "med:pmid:27395349:sec:conclusion:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Despite the increased risk associated with more recent hospitalization, the efficacy of sacubitril/valsartan therapy did not differ from that of enalapril according to the occurrence of or time from hospitalization for HF before screening, with respect to the primary endpoint or with respect to cardiovascular or all-cause mortality. Patients with recent HF decompensation requiring hospitalization were more likely to experience cardiovascular death or HF hospitalization than those who had never been hospitalized.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27395349", "sentence_id": "med:pmid:27395349:sec:conclusion:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.665444+00:00"}
{"doc_id": "med:pmid:27395349", "sentence_id": "med:pmid:27395349:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability.<h4>Background</h4>Despite the benefit of sacubitril/valsartan therapy shown in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, it has been suggested that switching from an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker should be\u00a0delayed until occurrence of clinical decompensation.<h4>Methods</h4>Outcomes were compared among patients who had prior hospitalization within 3 months of screening (n\u00a0=\u00a01,611 [19%]), between 3 and 6 months (n\u00a0= 1,009 [12%]), between 6 and 12 months (n\u00a0= 886 [11%]), >12\u00a0months (n\u00a0= 1,746 [21%]), or who had never been hospitalized (n\u00a0= 3,125 [37%]).<h4>Results</h4>Twenty percent of patients without prior HF hospitalization experienced a primary endpoint of cardiovascular death or heart failure (HF) hospitalization during the course of the trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27417000", "sentence_id": "med:pmid:27417000:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization.<h4>Objectives</h4>This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates of hospital readmission at 30-days following HF hospitalization compared with enalapril.<h4>Methods</h4>We assessed the risk of 30-day readmission for any cause following investigator-reported hospitalizations for HF in the PARADIGM-HF trial, which randomized 8,399 participants with HF and reduced ejection fraction to treatment with LCZ696 or enalapril.<h4>Results</h4>Accounting for multiple hospitalizations per patient, there were 2,383 investigator-reported HF hospitalizations, of which 1,076 (45.2%) occurred in subjects assigned to LCZ696 and 1,307 (54.8%) occurred in subjects assigned to enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27438344", "sentence_id": "med:pmid:27438344:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Importance</h4>The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27438344", "sentence_id": "med:pmid:27438344:sec:introduction:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sensitivity analyses demonstrated sacubitril/valsartan would remain cost-effective vs enalapril.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27438344", "sentence_id": "med:pmid:27438344:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan has been approved for use in heart failure (HF) with reduced ejection fraction in the United States and cost has been suggested as 1 factor that will influence the use of this agent. To estimate the cost-effectiveness of sacubitril/valsartan vs enalapril in the United States.<h4>Design, setting, and participants</h4>Data from US adults (mean [SD] age, 63.8 [11.5] years) with HF with reduced ejection fraction and characteristics similar to those in the PARADIGM-HF trial were used as inputs for a 2-state Markov model simulated HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27438344", "sentence_id": "med:pmid:27438344:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Hospital costs combined Medicare and private insurance reimbursement rates; medication costs included the wholesale acquisition cost for sacubitril/valsartan and enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27438344", "sentence_id": "med:pmid:27438344:sec:introduction:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sensitivity analyses were performed on key inputs including: hospital costs, mortality benefit, hazard ratio for hospitalization reduction, drug costs, and quality-of-life estimates.<h4>Main outcomes and measures</h4>Hospitalizations, quality-adjusted life-years (QALYs), costs, and incremental costs per QALY gained.<h4>Results</h4>The 2-state Markov model of US adult patients (mean age, 63.8 years) calculated that there would be 220 fewer hospital admissions per 1000 patients with HF treated with sacubitril/valsartan vs enalapril over 30 years.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27438344", "sentence_id": "med:pmid:27438344:sec:introduction:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The incremental costs and QALYs gained with sacubitril/valsartan treatment were estimated at $35\u202f512 and 0.78, respectively, compared with enalapril, equating to an incremental cost-effectiveness ratio (ICER) of $45\u202f017 per QALY for the base-case.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27438344", "sentence_id": "med:pmid:27438344:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27510447", "sentence_id": "med:pmid:27510447:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Accordingly, both the new US and European Society of Cardiology heart failure guidelines recommend sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in patients with chronic heart failure who are currently receiving an ACE inhibitor or ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27573608", "sentence_id": "med:pmid:27573608:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan resulted in 20% reduction in the incidence rate of death or HF hospitalization compared to enalapril in symptomatic HFrEF patients in the seminal PARADIGM-HF trial.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27618854", "sentence_id": "med:pmid:27618854:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Overall, the sacubitril/valsartan versus enalapril hazard ratio for the primary composite end point was 0.80 (95% confidence interval,0.73-0.87;P<0.001) and for cardiovascular death was0.80 (0.71-0.89;P<0.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27618854", "sentence_id": "med:pmid:27618854:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27747488", "sentence_id": "med:pmid:27747488:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial of 8399 subjects with HFrEF, treatment with the ARNi LCZ696 (sacubitril/valsartan) was associated with statistically important reductions in cardiovascular death, all-cause mortality, and the composite of cardiovascular death or heart failure hospitalization in comparison with enalapril.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27804100", "sentence_id": "med:pmid:27804100:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A 63-year-old woman previously stable on a regimen of atorvastatin 40\u00a0mg daily, carvedilol 25\u00a0mg twice daily, digoxin 0.125\u00a0mg daily, furosemide 40\u00a0mg daily, spironolactone 25\u00a0mg daily, rivaroxaban 15\u00a0mg daily, and enalapril 20\u00a0mg twice daily for heart failure developed rhabdomyolysis 26\u00a0days after enalapril was stopped and sacubitril/valsartan (Entresto\u2122) started.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27868321", "sentence_id": "med:pmid:27868321:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The rates of dementia-related AEs in both treatment groups in PARADIGM-HF were similar to those in three other recent trials in HFrEF. We found no evidence that sacubitril/valsartan, compared with enalapril, increased dementia-related AEs, although longer follow-up may be necessary to detect such a signal and more sensitive tools are needed to detect lesser degrees of cognitive impairment.", "sentiment_label": "NEU", "sentiment_score": 0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27868321", "sentence_id": "med:pmid:27868321:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM-HF which compared the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan with enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27868321", "sentence_id": "med:pmid:27868321:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The narrow SMQ search identified 27 dementia-related AEs: 15 (0.36%) on enalapril and 12 (0.29%) on sacubitril/valsartan [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.33-1.59].", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27908347", "sentence_id": "med:pmid:27908347:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with sacubitril/valsartan was\u00a0nearly twice as likely as enalapril to reduce NT-proBNP to values \u22641,000 pg/ml. (", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27908347", "sentence_id": "med:pmid:27908347:sec:conclusion:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial)\u00a0[PARADIGM-HF]; NCT01035255.).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27908347", "sentence_id": "med:pmid:27908347:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance of changes in NP from baseline is unclear.<h4>Objectives</h4>The authors assessed whether a reduction in N-terminal pro-B-type NP (NT-proBNP) was associated with a decrease in HF hospitalization and cardiovascular mortality (primary endpoint) in patients with HF and reduced ejection fraction, whether treatment with sacubitril/valsartan reduced NT-proBNP below specific partition values more than enalapril, and whether the relationship between changes in NT-proBNP and changes in the primary endpoint were dependent on assigned treatment.<h4>Methods</h4>In PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial), baseline NT-proBNP was measured in 2,080 patients; 1,292 had baseline values >1,000 pg/ml and were reassessed at 1\u00a0and\u00a08 months.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:27908347", "sentence_id": "med:pmid:27908347:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In sacubitril/valsartan-treated patients, median NT-proBNP was significantly lower 1 month after randomization than in enalapril-treated patients, and it fell to\u00a0\u22641,000 pg/ml in 31% versus 17% of patients treated with sacubitril/valsartan and enalapril, respectively.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:28292483", "sentence_id": "med:pmid:28292483:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Unless priced lower than enalapril (<\u20ac0.045 per day), sacubitril/valsartan is very unlikely to be cost-saving/dominant.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:28292483", "sentence_id": "med:pmid:28292483:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction.<h4>Objectives</h4>To determine the incremental cost-effectiveness of sacubitril/valsartan compared with enalapril in the Netherlands using the clinical data from the PARADIGM-HF trial.<h4>Methods</h4>To compare sacubitril/valsartan and enalapril in a cost-effectiveness study, a Markov model was developed using the effectiveness data from the PARADIGM-HF trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:28785452", "sentence_id": "med:pmid:28785452:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARADIGM-HF study demonstrated robust superiority of ARNI compared with enalapril in patients with chronic symptomatic HFrEF, raising the question of whether ACEI should still have a role in the management of HFrEF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:28905031", "sentence_id": "med:pmid:28905031:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan may be used instead of an ACE inhibitor or ARB in patients with chronic symptomatic HFrEF class II or III to further reduce morbidity and mortality.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:33119090", "sentence_id": "med:pmid:33119090:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the beneficial effect of sacubitril/valsartan (SAC/VAL) compared to enalapril was consistent across ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy (NICM) groups, the PARADIGM-HF study did not analyse the effect of ventricular remodelling on patients with different aetiologies, which may affect clinical treatment outcomes.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:34969175", "sentence_id": "med:pmid:34969175:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The purpose of this post hoc study was to analyse the effect of sacubitril/valsartan, compared to enalapril, on the incidence of ventricular arrhythmias.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:34969175", "sentence_id": "med:pmid:34969175:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril/valsartan reduced the risk of a ventricular arrhythmia (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.62-0.95; p\u00a0=\u00a00.015) and the composite arrhythmia outcome (HR 0.79, 95% CI 0.65-0.97; p\u00a0=\u00a00.025).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:34989105", "sentence_id": "med:pmid:34989105:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In patients with heart failure, sacubitril/valsartan reduced the risk of serious adverse renal outcomes and slowed decline in eGFR, compared with valsartan or enalapril, independent of baseline renal function.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:34989105", "sentence_id": "med:pmid:34989105:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The composite renal outcome occurred in 70 of 6594 patients (1.1%) in the sacubitril/valsartan group and in 123 of 6601 patients (1.9%) in the valsartan or enalapril group (hazard ratio 0.56, 95% confidence interval [CI] 0.42-0.75; p\u2009<\u20090.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:34989105", "sentence_id": "med:pmid:34989105:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean eGFR change was -1.8 (95% CI -1.9 to -1.7) ml/min/1.73 m<sup>2</sup> /year for the sacubitril/valsartan group, compared with -2.4 (95% CI -2.5 to -2.2) ml/min/1.73 m<sup>2</sup> /year for the valsartan or enalapril group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35035857", "sentence_id": "med:pmid:35035857:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Studies have shown sacubitril/valsartan can further reduce the risk of cardiovascular death or hospitalization for heart failure by 20% compared with enalapril.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35081164", "sentence_id": "med:pmid:35081164:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan was similar to either enalapril or valsartan in preventing the occurrence of AF in patients with HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35081164", "sentence_id": "med:pmid:35081164:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was no significant difference in the prevention of AF occurrence between the sacubitril/valsartan group and the control group (enalapril or valsartan) in patients with HF (RR 1.07, 95%CI 0.95 to 1.19; I2 4%).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35200707", "sentence_id": "med:pmid:35200707:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF study in 2014.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35222898", "sentence_id": "med:pmid:35222898:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril valsartan and valsartan have been shown to reduce the mortality and morbidity of cardiovascular diseases.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35282662", "sentence_id": "med:pmid:35282662:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Secondary outcomes occurred in 13 participants (20.3%) in the ARNI group and 22 participants (34.4%) in the enalapril group [hazard ratio (HR), 0.56; 95% CI: 0.28 to 1.12; P=0.102].", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35282662", "sentence_id": "med:pmid:35282662:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The incidence of outpatient HF or HF hospitalization in the ARNI group was significantly lower than that in the enalapril group (HR, 0.36; 95% CI: 0.14 to 0.94; P=0.037).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35282662", "sentence_id": "med:pmid:35282662:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We found that NT-proBNP concentration decreased more in the ARNI group than in the enalapril group [4 weeks: ratio of ARNI <i>vs.</i> enalapril 0.36, 95% confidence interval (CI): 0.24 to 0.52, P<0.001; 12 weeks: 0.54, 95% CI: 0.35 to 0.79, P<0.001; 24 weeks: 0.53, 95% CI: 0.32 to 0.83, P<0.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35282662", "sentence_id": "med:pmid:35282662:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "When compared to the enalapril group, the ARNI group patients had a significant reduction in LVEDV (P<0.001) and LVESV (P<0.001), and an improvement in LVEF (P=0.011) at 24 weeks.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35343504", "sentence_id": "med:pmid:35343504:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARADIGM-HF trial demonstrated a favorable effect of sacubitril/valsartan over enalapril in terms of mortality and heart failure hospitalization rate reduction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.681547+00:00"}
{"doc_id": "med:pmid:35400328", "sentence_id": "med:pmid:35400328:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan has revealed superior glycemic and blood pressure control compared with enalapril and irbesartan in patients with heart failure and type 2 diabetes and in individuals with chronic kidney disease.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35469709", "sentence_id": "med:pmid:35469709:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARADIGM-HF trial demonstrated a significant advantage of sacubitril/valsartan over enalapril on the reduction of cardiovascular (CV) mortality and heart failure hospitalizations rates.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The ARNI study group showed better safety and efficacy outcomes at the end of 6 months follow-up compared to ACEI group.", "sentiment_label": "POS", "sentiment_score": 3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To compare the safety and efficacy of valsartan/sacubitril (angiotensin receptor neprilysin inhibitor [ARNI]) against enalapril (angiotensin-converting enzyme inhibitor [ACEI]) in patients with acute heart failure at 6-month follow-up.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients were divided in two groups: valsartan/sacubitril (ARNI) group and enalapril (ACEI).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Readmission for heart failure were seen significantly higher in ACEI group than ARNI group (p value\u00a0=\u00a00.001).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 200 patients were included in the present study, 100 each in ARNI and ACEI group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean age of the population was 61.2\u00a0\u00b1\u00a08.4 years and 62.6\u00a0\u00b1\u00a08.6 years in ARNI group and ACEI group, respectively.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean maximum tolerated dose by population in ARNI group was 203.6\u00a0mg and 8.9\u00a0mg in ACEI group.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35560696", "sentence_id": "med:pmid:35560696:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the EVALUATE-HF trial (n\u00a0=\u00a0464) were randomized to sacubitril/valsartan or enalapril for 12\u2009weeks, followed by 12-week open-label sacubitril/valsartan.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35702942", "sentence_id": "med:pmid:35702942:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all-cause mortality in patients with ambulatory heart failure and reduced ejection fraction (HFrEF), in particular when it is maximally up-titrated.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35717169", "sentence_id": "med:pmid:35717169:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35717169", "sentence_id": "med:pmid:35717169:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Across the spectrum of LVEF, sacubitril/valsartan reduced new insulin therapy (HR: 0.75, 95% CI 0.63-0.89, P\u2009=\u20090.001), compared with enalapril or valsartan.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35761118", "sentence_id": "med:pmid:35761118:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Frail patients in randomised trials of sacubitril/valsartan, aliskiren, or enalapril had twice the risk of mortality (hazard ratio [HR] 2.09, 1.62-2.71) and hospitalisations (HR 1.82, 1.37-2.41) compared with robust patients, which may reflect responsiveness to medications and/or factors unrelated to medication use.", "sentiment_label": "NEU", "sentiment_score": -0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35874853", "sentence_id": "med:pmid:35874853:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients were randomized to receive oral treatment with sacubitril/valsartan or enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35874853", "sentence_id": "med:pmid:35874853:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After 6 months, sacubitril/valsartan improved significantly the following parameters compared with enalapril (all <i>p</i>\u2009<\u20090.05): LVEF (47.07\u2009\u00b1\u20096.93% vs. 43.47\u2009\u00b1\u20097.95%); TAPSE (15.33\u2009\u00b1\u20091.31\u00a0vs. 14.78\u2009\u00b1\u20091.36\u2009mm); sPAP (36.76\u2009\u00b1\u200914.32\u00a0vs. 42.26\u2009\u00b1\u200912.07\u2009mmHg); and TAPSE/sPAP ratio (0.50\u2009\u00b1\u20090.23 vs. 0.39\u2009\u00b1\u20090.14), respectively.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:35874853", "sentence_id": "med:pmid:35874853:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The comparative effects of sacubitril/valsartan versus\u00a0enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36132549", "sentence_id": "med:pmid:36132549:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, HFpEF patients that underwent ARNI treatment achieved better outcomes than did patients that underwent ACEI treatment.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36133814", "sentence_id": "med:pmid:36133814:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan has been commonly compared to enalapril in cost effectiveness analysis and has been found to be similar to that of SGLT2i but was not considered a cost-effective treatment for heart failure with reduced ejection fraction in Thailand and Singapore with the current economic evaluation evidences.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36530836", "sentence_id": "med:pmid:36530836:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b><i>Background:</i></b> Post hoc analysis of the PARADIGM-HF trial showed that sacubitril/valsartan (S/V) was more effective than enalapril in lowering HbA1c in patients with heart failure and diabetes.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36601956", "sentence_id": "med:pmid:36601956:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study aimed to evaluate the pharmacokinetics and pharmacodynamics of single doses of sacubitril/valsartan (Part 1), and the efficacy and safety of sacubitril/valsartan versus enalapril administered twice daily for 52 weeks (Part 2) in pediatric patients with HF due to left ventricular systolic dysfunction with biventricular heart physiology.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36685156", "sentence_id": "med:pmid:36685156:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36808581", "sentence_id": "med:pmid:36808581:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor-ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compared with enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36808581", "sentence_id": "med:pmid:36808581:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In Argentina the cost-per quality adjusted life-year (QALY) gained for sacubitril/valsartan versus enalapril was 391,158 ARS and 376,665 ARS for a social security and a private payer, respectively, at a 30- year horizon.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36812948", "sentence_id": "med:pmid:36812948:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In sequential run-in phases, patients were titrated to enalapril 10\u00a0mg twice daily and then sacubitril/valsartan 97\u00a0mg/103\u00a0mg twice daily (in PARADIGM-HF) or valsartan 80\u00a0mg twice daily and then sacubitril/valsartan 49\u00a0mg/51\u00a0mg twice daily (in PARAGON-HF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36943907", "sentence_id": "med:pmid:36943907:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan increased the ucGMP/BNP ratio, compared with enalapril, and the effect of sacubitril/valsartan on clinical outcomes was not modified by baseline ucGMP/BNP ratio.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36943907", "sentence_id": "med:pmid:36943907:sec:methods:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We examined the relationship between ucGMP/BNP ratio and clinical outcomes, the effect of sacubitril/valsartan, compared with enalapril, on the ucGMP/BNP ratio, and the efficacy of sacubitril/valsartan on clinical outcomes according to baseline ucGMP/BNP ratio in PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36943907", "sentence_id": "med:pmid:36943907:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with baseline, the ucGMP/BNP ratio at 1 month and 8 months after randomization was higher with sacubitril/valsartan than with enalapril: ratio of geometric mean ratios at 1 month, 1.38 (95% CI, 1.27-1.51) and 8 months, 1.32 (95% CI, 1.20-1.45), and this difference was consistent across tertiles of ucGMP/BNP ratio at baseline (<i>P</i><sub>interaction</sub>=0.19 and 0.91, respectively).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:36943907", "sentence_id": "med:pmid:36943907:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The effect of sacubitril/valsartan, compared with enalapril, was consistent across tertiles of ucGMP/BNP ratio at baseline for all outcomes (<i>P</i><sub>interaction</sub> \u22650.31).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37042870", "sentence_id": "med:pmid:37042870:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "They received sacubitril/valsartan or valsartan instead of the more commonly used angiotensin-converting enzyme inhibitor enalapril for heart failure, in addition to standard medical therapy for heart failure.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37043670", "sentence_id": "med:pmid:37043670:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The results of this study show that sacubitril/valsartan can be used in patients with AMI instead of enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37043670", "sentence_id": "med:pmid:37043670:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study focuses on the relevant indexes of VR in patients with AMI, in which, the intervention effects of sacubitril/valsartan and enalapril were compared, guiding the clinical treatment.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37104912", "sentence_id": "med:pmid:37104912:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study aimed to estimate the financial and economic impact of sacubitril/valsartan compared with enalapril for the treatment and prevention of hospitalization/rehospitalization because of heart failure with reduced ejection fraction (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37104912", "sentence_id": "med:pmid:37104912:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In 5 years, the total cost of treating patients with HFrEF with sacubitril/valsartan at current market coverage and annual growth conditions is \u20b115.430 billion, which is \u20b111.077 billion higher than fully treating with enalapril only.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37104912", "sentence_id": "med:pmid:37104912:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The total required additional investment with treatment of sacubitril/valsartan compared with the full enalapril arm are \u20b1407 million (at 30-day coverage), \u20b1800 million (at 60-day coverage), and \u20b11.181 billion (at 90-day coverage).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37143752", "sentence_id": "med:pmid:37143752:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan is associated with better outcomes and may be cost-effective compared to enalapril for the management of HFrEF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37143752", "sentence_id": "med:pmid:37143752:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To assess the cost-effectiveness of sacubitril/valsartan compared with enalapril in patients with heart failure with reduced ejection (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37143752", "sentence_id": "med:pmid:37143752:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "All relevant full economic evaluation studies of sacubitril/valsartan versus enalapril for the treatment of patients with HFrEF were identified using ad hoc search strategies.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37143752", "sentence_id": "med:pmid:37143752:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37240819", "sentence_id": "med:pmid:37240819:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Irrespective of anemia status, sacubitril/valsartan compared with enalapril, decreased mortality and hospitalization.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in\u00a0Heart Failure [PARADIGM-HF] trial; NCT01035255).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients assigned to sacubitril/valsartan were less likely to develop anemia at 12\u00a0months (321 of 2,806 [11.4%]) compared with patients randomized to enalapril (440 of 2,824 [15.6%]) (OR: 0.70 [95%\u00a0CI: 0.60-0.81]; P\u00a0< 0.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan, compared with enalapril, decreased the risk of cardiovascular death or heart failure hospitalization similarly in patients with (HR: 0.84; 95%\u00a0CI: 0.71-1.00) and without anemia (HR: 0.78 [95%\u00a0CI: 0.71-0.87]; P value for interaction\u00a0=\u00a00.478).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Between baseline and 12\u00a0months, hemoglobin decreased by 1.5 g/L (95%\u00a0CI: 1.2-1.7 g/L) with sacubitril/valsartan compared with 2.3 g/L (95%\u00a0CI: 2.0-2.6 g/L) with enalapril: mean difference 0.8 g/L (95%\u00a0CI: 0.5-1.2 g/L; P\u00a0< 0.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37635080", "sentence_id": "med:pmid:37635080:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARALLEL-HF study assessed the efficacy and safety of sacubitril/valsartan vs. enalapril in Japanese patients with chronic heart failure with reduced ejection fraction (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37635080", "sentence_id": "med:pmid:37635080:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At OLE baseline, higher concentrations of B-type natriuretic peptide (BNP) and urine cGMP, and lower concentrations of N-terminal pro B-type natriuretic peptide (NT-proBNP), were observed in the sacubitril/valsartan core group (patients who received sacubitril/valsartan in both the core and extension study) than in the enalapril core group (patients who received enalapril in the core study and were then transitioned to sacubitril/valsartan).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37941691", "sentence_id": "med:pmid:37941691:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is superior to enalapril for chronic heart failure (CHF) with reduced ejection fraction (EF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37989299", "sentence_id": "med:pmid:37989299:sec:conclusion:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The efficacy of sacubitril/valsartan compared with enalapril was consistent across baseline SBP tertiles in Japanese patients from the PARALLEL-HF study.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37989299", "sentence_id": "med:pmid:37989299:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "No significant difference was observed between sacubitril/valsartan and enalapril for the composite outcome of cardiovascular death and HF hospitalization across SBP tertiles (P-interaction=0.2682).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37989299", "sentence_id": "med:pmid:37989299:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the P-interaction value was not significant (0.2106), a greater reduction in NT-proBNP with sacubitril/valsartan compared with enalapril was observed in patients with SBP >130 mmHg (P=0.0076).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:37989299", "sentence_id": "med:pmid:37989299:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The incidence of hypotension-related events and reduction or discontinuation of treatment due to hypotension-related events was higher in the lower SBP subgroup, and these events were more frequent in the sacubitril/valsartan than enalapril group.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Pooled analysis showed that the risk of all-cause mortality was higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan (risk ratio [RR]: 0.57; 95% CI: 0.31 to 1.04).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.697256+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Risk of cardiovascular mortality was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.75; 95% CI: 0.62 to 0.91).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The risk of cardiovascular hospitalization was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.76; 95% CI: 0.66 to 0.86).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In conclusion, our meta-analysis of nine studies underscores the superior clinical performance of sacubitril/valsartan compared to enalapril in managing patients with heart failure.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparison of Outcomes Between Sacubitril/Valsartan and Enalapril in Patients With Heart Failure: A Systematic Review and Meta-Analysis.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38330576", "sentence_id": "med:pmid:38330576:sec:conclusion:sent:18", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38330576", "sentence_id": "med:pmid:38330576:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38356826", "sentence_id": "med:pmid:38356826:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In CHF patients, the combination of LBBP with sacubitril/valsartan had a better therapeutic effect compared to LBBP with enalapril, with more effective improvement of the cardiopulmonary function, reduction of myocardial injury, and improvement in quality of life.", "sentiment_label": "POS", "sentiment_score": 5.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38356826", "sentence_id": "med:pmid:38356826:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To assess the efficacy of left bundle branch pacing (LBBP) combined with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure (CHF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38356826", "sentence_id": "med:pmid:38356826:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We divided the data into two treatment groups for the analysis: 71 patients received LBBP combined with sacubitril/valsartan treatment (sacubitril/valsartan group), and 67 received LBBP combined with enalapril treatment (enalapril group).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38356826", "sentence_id": "med:pmid:38356826:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparison of the efficacy of combining left bundle branch pacing with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure: A retrospective observational analysis.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38508844", "sentence_id": "med:pmid:38508844:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart\u00a0Failure Episode [PIONEER-HF]; NCT02554890; Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event [HFpEF Decompensation] Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation [PARAGLIDE-HF]; NCT03988634).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38508844", "sentence_id": "med:pmid:38508844:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Data from randomized trials of sacubitril/valsartan in HF patients with EF\u00a0\u226440% (PIONEER-HF [Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart\u00a0Failure Episode] trial) and >40% (PARAGLIDE-HF [Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF] trial) following recent worsening heart failure (WHF) were pooled to examine treatment effect across the EF spectrum.", "sentiment_label": "NEG", "sentiment_score": -3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38508844", "sentence_id": "med:pmid:38508844:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38663899", "sentence_id": "med:pmid:38663899:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We report a case in which bilateral renal artery revascularisation allowed the safe reintroduction of enalapril (and subsequently sacubitril valsartan) in a patient with severe left ventricular systolic dysfunction.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:38764991", "sentence_id": "med:pmid:38764991:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b>Background:</b> The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to enalapril in patients with reduced ejection fraction (HFrEF).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39111953", "sentence_id": "med:pmid:39111953:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200\u00a0mg twice daily vs enalapril 10\u00a0mg twice daily added to standard of care treatment for HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39111953", "sentence_id": "med:pmid:39111953:sec:abstract:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC [PARACHUTE-HF]; NCT04023227).", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39111953", "sentence_id": "med:pmid:39111953:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39210725", "sentence_id": "med:pmid:39210725:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Participants with chronic HF, New York Heart Association classes II through IV symptoms, and elevated natriuretic peptides were randomized to treatment with either sacubitril/valsartan or a renin-angiotensin system inhibitor (RASi)-enalapril in the PARADIGM-HF trial or valsartan in the PARAGON-HF trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39210725", "sentence_id": "med:pmid:39210725:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan vs RASi (enalapril or valsartan).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39262640", "sentence_id": "med:pmid:39262640:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In PARALLEL-HF, in which 223 patients with HF and reduced ejection fraction (HFrEF) were randomized to the angiotensin-receptor neprilysin inhibitor (sacubitril/valsartan) or enalapril, 97 (43%) received influenza vaccination.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Incidence of hypotension-related AEs was higher in the sacubitril/valsartan versus enalapril group but did not affect risk of cardiovascular death or HF hospitalization, which was similar between treatment groups.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARALLEL-HF trial showed that treatment with sacubitril/valsartan resulted in more symptomatic hypotension versus enalapril in Japanese patients with heart failure (HF) and reduced ejection fraction, similar to PARADIGM-HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This post-hoc analysis characterized hypotension-related adverse events (AEs) and their effects on efficacy using data from PARALLEL-HF, in which patients received sacubitril/valsartan 200\u202fmg twice daily or enalapril 10\u202fmg twice daily.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of 223 patients, 28.2\u202f% experienced hypotension-related AEs and incidence was higher with sacubitril/valsartan versus enalapril (hazard ratio, 2.2; 95\u202f% CI, 1.3-3.8; p\u202f=\u202f0.0027).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Hypotension-related AEs leading to treatment discontinuation were not significantly different for sacubitril/valsartan versus enalapril (3.4\u202f% vs 6.9\u202f%, p\u202f=\u202f0.5957).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Reduction in risk of cardiovascular death or HF hospitalization was similar with sacubitril/valsartan versus enalapril in patients with or without hypotension-related AEs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril/valsartan or enalapril: Results from the PARALLEL-HF study.", "sentiment_label": "NEG", "sentiment_score": -3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39319469", "sentence_id": "med:pmid:39319469:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39319469", "sentence_id": "med:pmid:39319469:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39319469", "sentence_id": "med:pmid:39319469:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39319469", "sentence_id": "med:pmid:39319469:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 375 children (mean age, 8.1\u00b15.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although both asymptomatic and symptomatic hypotension during treatment with sacubitril/valsartan or enalapril were associated with worse outcomes, the benefits of sacubitril/valsartan were maintained (or even enhanced) in patients experiencing hypotension.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In a post hoc analysis of PARADIGM-HF, the efficacy and safety of sacubitril/valsartan compared to enalapril were estimated using time-updated Cox proportional hazards models.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The safety of sacubitril/valsartan vs enalapril was also maintained regardless of the occurrence of hypotension.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Discontinuation of randomized treatment was less common with sacubitril/valsartan vs enalapril in patients experiencing asymptomatic and symptomatic hypotension.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, the effect of sacubitril/valsartan on the primary outcome was not diminished in patients experiencing hypotension compared to those who did not: the HR for sacubitril/valsartan vs enalapril was 0.80 (95% CI: 0.72-0.89) for no hypotension, 0.87 (95% CI: 0.70-1.08) for asymptomatic hypotension, and 0.51 (95% CI: 0.38-0.69) for symptomatic hypotension (P<sub>interaction</sub>\u00a0=\u00a00.01), and this was also true for cardiovascular and all-cause deaths.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39439294", "sentence_id": "med:pmid:39439294:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PARADIGM-HF and PARAGON-HF were randomized trials testing sacubitril/valsartan versus enalapril or valsartan, respectively, in patients with HF and LVEF\u2009\u226440% (PARADIGM-HF) or LVEF \u226545% (PARAGON-HF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39544776", "sentence_id": "med:pmid:39544776:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39544776", "sentence_id": "med:pmid:39544776:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The observation group was comprised of 31 patients treated with sacubitril/valsartan (LCZ696) sodium tablets, while the control group, including 32 patients, received enalapril maleate tablets.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan may be more effective than enalapril in reducing the risk of death in patients not treated with a beta-blocker compared to those treated with a beta-blocker, but is effective regardless of beta-blocker use.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Safety outcomes related to sacubitril/valsartan versus enalapril did not differ according to background beta-blocker use.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We examined the effect of sacubitril/valsartan compared to enalapril on outcomes according to background beta-blocker treatment in the 8399 patients with heart failure with reduced ejection fraction enrolled in PARADIGM-HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at discharge were evaluated across 3 time periods.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:introduction:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Main outcomes and measures</h4> Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39720381", "sentence_id": "med:pmid:39720381:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Combining beta-blockers and ACE inhibitors, or integrating them with newer agents such as angiotensin receptor-neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs), provides an additive benefit, improving long-term survival and reducing heart failure-related hospitalizations.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.713008+00:00"}
{"doc_id": "med:pmid:39792134", "sentence_id": "med:pmid:39792134:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF)\u2009>40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.<h4>Methods and results</h4>This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39864551", "sentence_id": "med:pmid:39864551:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The most common adverse events were hypotension and elevated serum potassium levels, though these were minimal and did not require discontinuation of ARNI therapy. Sacubitril/valsartan is a promising alternative to ARB or ACEi in managing RH, offering superior blood pressure reductions and potential benefits in reversing cardiac remodeling, while maintaining a favorable safety profile with minimal risk of serious adverse events.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the sacubitril/valsartan cohort when compared with the ACEi/ARB cohort had lower annual rates of all-cause hospitalizations [incidence rate ratio (IRR): 0.81, 95% confidence interval (CI): 0.75-0.89, P\u00a0<\u00a00.001], cardiovascular (CV) hospitalizations (IRR: 0.80, 95% CI: 0.73-0.87, P\u00a0<\u00a00.001) and HF hospitalizations (IRR: 0.86, 95% CI: 0.78-0.95, P\u00a0=\u00a00.002). Among patients with de novo HFrEF, sacubitril/valsartan (compared with that of ACEi/ARB) was associated with fewer all-cause, CV and HF hospitalizations.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:methods:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We examined the effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum\u00ae dataset in the United States. This retrospective cohort study included adult patients with de novo HFrEF (diagnosed \u226430\u00a0days) with left ventricular ejection fraction (LVEF) \u226440% who were first prescribed with sacubitril/valsartan or ACEi/ARB from 1 January 2016 to 31 March 2020.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The primary endpoint (all-cause hospitalization) and secondary endpoints were analysed in propensity score-matched cohorts. A cohort of 3290 patients with de novo HFrEF who were prescribed with sacubitril/valsartan and a propensity-matched cohort of 6580 patients who were prescribed with ACEi/ARB were analysed.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39922597", "sentence_id": "med:pmid:39922597:sec:conclusion:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Conversely, the prescription of furosemide at discharge (adjusted OR 2.25; 95% CI 95% 1.29 to 3.94; p<0.01) and a previous genitourinary infection (adjusted OR 4.02; 95% CI 1.67 to 9.68; p<0.01) were associated with higher risk of 30-day all-cause death and urgent rehospitalisation. In our study, early adoption of guideline-recommended medical therapy is still limited, with a significant rise in SGLT2i prescriptions after January 2022 and a lower risk of the composite of all-cause death and urgent readmissions at 30 days restricted to the use of ACEi/ARB/ARNi.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39922597", "sentence_id": "med:pmid:39922597:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In multivariate analysis, the use of ACEi/ARB/ARNi was associated with a lower risk of 30-day all-cause death and urgent rehospitalisation (adjusted OR 0.38; 95% CI 0.24 to 0.59; p<0.01).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39939202", "sentence_id": "med:pmid:39939202:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The prescription of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)/angiotensin receptor neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists at any dose (52% vs 80%; p<0.01, 25% vs 52%; p<0.01, respectively) were lower in non-cardiology than in cardiology wards, but there was no difference between wards for beta blockers.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39939202", "sentence_id": "med:pmid:39939202:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Increased age was associated with less likelihood of the prescription of ACEIs/ARBs/ARNIs and mineralocorticoid receptor antagonists at any dose and \u226550% target dose.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39970741", "sentence_id": "med:pmid:39970741:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/Valsartan vs ACE Inhibitors or\u00a0ARBs: A Systematic Review and Meta-Analysis of Randomized Trials.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with sacubitril/valsartan or enalapril prevented deterioration of myocardial function at 6\u00a0months in patients with hematologic malignancies treated with BMT.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The authors investigated whether early initiation of sacubitril/valsartan or enalapril could be helpful to prevent CTRCD in patients undergoing BMT.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We randomized 90 patients with preserved left ventricular ejection fraction (LVEF) after BMT to sacubitril/valsartan, enalapril, or no cardioprotective medication (controls).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients treated with sacubitril/valsartan or enalapril for 6\u00a0months did not show a deterioration of LV GLS or LVEF (P\u00a0>\u00a00.05).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The percent improvement of GWW and GWE was greater in the sacubitril/valsartan compared to enalapril or control group (P\u00a0=\u00a00.044 and P\u00a0=\u00a00.011, respectively) at 6\u00a0months.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A Randomized Controlled Trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40091512", "sentence_id": "med:pmid:40091512:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prescription rates were 50% for BB, 74.1% for ACEi/ARB/ARNI, 14.8% for SGLT2i, 47% for MRA, and 19.6% for ISDN/HYD.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40101251", "sentence_id": "med:pmid:40101251:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean number of days to achieve titration ranged from 20.2 days for mineralocorticoid receptor antagonist drugs, between 27.5 to 32.3 days for ACEI/ARB/ARNI drugs and 41.0 days for beta-blockers; 70 (79%) patients completed the satisfaction survey at least once, with more than 98% of survey questions receiving a positive response.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40115097", "sentence_id": "med:pmid:40115097:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Statistical comparison between two groups was performed, which focused on indicators of standardized management [proportion of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiography performed in the diagnosis of HF, application ratio of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), \u03b2-blockers in heart failure with reduced ejection fraction (HFrEF) patients, 1 week, 1 month, 3 months and 1 year follow-up rate] and clinical prognosis indicators (NT-proBNP level, 6-minute walking distance test, heart function grading, shorter average duration in hospital) at discharge, review of relevant indicators after 1 year, readmission rate and incidence of main adverse cardiovascular and cerebrovascular events (MACCEs) in 1 year. Compared to the control group, the proportion of patients using NT-proBNP (94.7% <i>vs.</i> 87.3%, P=0.03), echocardiography (88.7% <i>vs.</i> 78.7%, P=0.02), the ratio of patients using ACEI/ARB/ARNI (87.0% <i>vs.</i> 72.2%, P=0.03) and \u03b2-blocker (82.7% <i>vs.</i> 66.7%, P=0.03) before discharge, and the follow-up rate of each period after discharge (1 week, 90.7% <i>vs.</i> 80.0%, P=0.01; 1 month, 84.7% <i>vs.</i> 72.0%, P=0.01; 3 months, 76.7% <i>vs.</i> 64.0%, P=0.02; 1 year, 88.0% <i>vs.</i> 79.3%, P=0.04) was higher in the center group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40188960", "sentence_id": "med:pmid:40188960:sec:conclusion:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients with elevated NT-pro-BNP had high AMR, and those grouped by medication indicated that ACEI/ARB, sacubitril/valsartan, and trimetazidine might lower AMR in patients with elevated NT-pro-BNP. The DbCM-2B diagnostic criteria demonstrated a strong correlation with CMD.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40188960", "sentence_id": "med:pmid:40188960:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ACEI/ARB, sacubitril/valsartan, and trimetazidine might improve CMD in patients with DbCM.", "sentiment_label": "NEU", "sentiment_score": 0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sex-specific efficacy and safety of sacubitril/valsartan in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) remain unreported.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This post hoc analysis of PARADIGM-HF examined sex-based outcomes in patients with HF and reduced ejection fraction randomized to sacubitril/valsartan or enalapril.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril/valsartan reduced the risk of the primary end point to a similar extent in both sexes: hazard ratios, 0.76 (95% CI, 0.62-0.94) in women and 0.80 (95% CI, 0.73-0.89) in men (<i>P</i>-interaction=0.62).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40266448", "sentence_id": "med:pmid:40266448:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, no significant benefit was observed in patients with GFR <30 mL/min/1.73 m<sup>2</sup>. In HF patients with AKD, ARNi was associated with reduced all-cause mortality, MAKE, and readmission risks compared to ACEi, particularly with concurrent mineralocorticoids, diuretics, or beta-blockers.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40266448", "sentence_id": "med:pmid:40266448:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Propensity score matching (1:1) was applied to balance ARNi and ACEi groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40268473", "sentence_id": "med:pmid:40268473:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The effects of sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor [ARNI]) on myocardial tissue in heart failure (HF) with left ventricular ejection fraction (LVEF) <50% remain unclear.<h4>Methods and results</h4>Sixty-four HF outpatients with LVEF <50% were randomized to ARNI (switching from an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [ACEi/ARB] to ARNI) or control (continuing with ACEi/ARB).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40283370", "sentence_id": "med:pmid:40283370:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) has been shown to reduce heart failure (HF) hospitalizations and mortality when compared to conventionally administered HF medications (i.e. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40295134", "sentence_id": "med:pmid:40295134:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the ARNI group, if a patient was on an ACE inhibitor or angiotensin II receptor blocker before TAVI, it will be switched to ARNI 100 mg/day (50 mg two times per day) on the first postoperative day.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Scenario analysis demonstrated that initiation of ARNI alongside sodium-glucose cotransporter-2 inhibitor (SGLT-2i) produces more favorable ICER and ARNI without SGLT-2i. At the cost-effectiveness threshold of RM55 426 per QALY, ARNI is cost-effective compared with ACEI for the heart failure with reduced ejection fraction population.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study compared the costs and effectiveness of angiotensin receptor neprilysin inhibitor (ARNI) with angiotensin-converting enzyme inhibitor (ACEI) for the heart failure with reduced ejection fraction population from the Malaysian Ministry of Health's perspective.<h4>Methods</h4>A 3-state Markov model, with a monthly cycle, was constructed to estimate the lifetime healthcare costs, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) of ARNI and ACEI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The ICER was compared with Malaysian Ringgit (RM) 55 426 per QALY (one gross domestic product per capita). Despite ARNI being more expensive compared with ACEI, it gained more QALYs, resulting in an ICER of RM46 498 per QALY.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We found high frequencies of prescription of GDMT for HFrEF, considering the therapeutic goals recommended by cardiology guidelines, but, prescription of target doses were low in ACEi, ARB or ARNi and beta-blockers.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Only 21,2% were prescribed GDMT target doses of enalapril, losartan or ARNi and 52,3% of beta-blockers.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "93.1% were prescribed ACEi, ARB or ARNi, 95.8% betablockers, 69.2% spironolactone and 8% the combination hydralazine/isosorbide-dinitrate.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "71,7% were using enalapril, losartan or ARNi above 50% of GDMT target doses; 81,2% were using beta-blockers and 100% were using spironolactone.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:discussion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PANORAMA-HF trial demonstrated significant N-terminal pro-B-type natriuretic peptide (NT-proBNP) reductions in paediatric patients with left ventricular systolic dysfunction with sacubitril/valsartan or enalapril treatment over 52\u00a0weeks.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Associations between baseline NT-proBNP levels, changes post-baseline and the risk of HF clinical events in paediatric patients on sacubitril/valsartan or enalapril were assessed.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40389107", "sentence_id": "med:pmid:40389107:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study investigated the effect of uptitration of sacubitril/valsartan (Sac/Val) compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level within current guideline-directed medical therapy in acute heart failure (AHF).<h4>Methods and results</h4>This was the secondary analysis in the Program Angiotensin-Neprilysin Inhibition in Admitted Patients with Worsening Heart Failure (PREMIER) study.", "sentiment_label": "NEG", "sentiment_score": -3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:introduction:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "During a mean follow-up of 2.2 and 2.3 years, dementia occurred in 200 (2.9%) sacubitril/valsartan users and 980 (3.5%) ACEI/ARB users, respectively.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:introduction:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan showed a 16% lower risk of dementia compared with ACEI/ARB (HR 0.84; 95% CI 0.72-0.98).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.728707+00:00"}
{"doc_id": "med:pmid:40418165", "sentence_id": "med:pmid:40418165:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs.", "sentiment_label": "NEU", "sentiment_score": 0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40418165", "sentence_id": "med:pmid:40418165:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI. Randomized controlled trials (RCTs) were pooled from PubMed and Cochrane databases.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40448468", "sentence_id": "med:pmid:40448468:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients who received triple GDMT therapy with a SGLTi or MRA added to beta blocker and ACEi/ARB/ARNi therapy at discharge were compared.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40450497", "sentence_id": "med:pmid:40450497:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We systematically evaluated sacubitril/valsartan (S/V) effects on the renal outcomes of patients with acute or chronic heart failure (HF) receiving angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).<h4>Method</h4>Five (5) databases were searched for randomised controlled trials (RCTs) comparing S/V vs ACEI or ARB in adult patients with HF until 2 September 2023.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study included two groups: the ARNI group included forty patients prescribed ARNI, and the ACEI group included forty patients prescribed ACEI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After a 6-month follow-up period, there was a significant reduction in LV-indexed volumes in the ARNI group (<i>P</i> < 0.001) and indexed left atrial volumes (<i>P</i> = 0.013) compared to the ACEI group.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was a significant improvement in the ARNI group regarding LVEF (<i>P</i> = 0.011), 2D GLS (<i>P</i> < 0.001), and 3D GLS compared to the ACEI group, but no significant change in the LV mass index.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40470816", "sentence_id": "med:pmid:40470816:sec:conclusion:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A significant association between CRT and the likelihood of ACEi/ARB/ARNi and MRA optimization (OR 1.22, 95% CI 1.04-1.44, and OR 1.25, 95% CI 1.05-1.50, respectively) was observed in the per-protocol analysis. In this large nationwide real-world population with HFrEF, CRT implantation was associated with enabled use/dose of heart failure GDMT and decreased loop diuretic need (use/dose).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40486108", "sentence_id": "med:pmid:40486108:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Substituting ACEIs/ARBs with ARNIs significantly improved the NYHA functional class (log odds ratio [log OR] 0.67, 95% CI 0.15-1.19; <i>p</i> = 0.01).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40540017", "sentence_id": "med:pmid:40540017:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Target doses of CDMT were achieved for 27% of males on ACEi/ARB/ARNI, 28% on BB, and 23% on MRA.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40542996", "sentence_id": "med:pmid:40542996:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The highest incidence of HK was observed with the combination of angiotensin converting enzyme inhibitor (ACEi)/angiotensin ii receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitor (ARNi)+ mineralocorticoid receptor antagonists (MRAs) (24.4%), followed by the triple therapy ACEi/ARB/ARNi+ sodium glucose cotransporter-2 inhibitor (SGLT2i)+MRA (10.9%), and ACEi/ARB/ARNi\u2009+\u2009SGLT2i (2.2%).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40660106", "sentence_id": "med:pmid:40660106:sec:discussion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Notably, 82% of patients were initiated on three or four drug classes concurrently at the start of treatment, most commonly including RAS inhibitors, MRAs, and beta-blockers, with a preference for ARNI over ACE inhibitors or ARBs. Foundational therapies were widely prescribed and frequently initiated concurrently in the management of HFrEF at a tertiary care hospital in Vietnam.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40689605", "sentence_id": "med:pmid:40689605:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, ARNI increased symptomatic hypotension risk (RR: 1.33; 95% CI: 1.04-1.71; <i>p</i>\u2009=\u20090.024). initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.<h4>Protocol registration</h4>PROSPERO: CRD42024618027.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40689605", "sentence_id": "med:pmid:40689605:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF. Meta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, WOS, Embase, and CENTRAL up to November 2024.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40718065", "sentence_id": "med:pmid:40718065:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients receiving triple therapy with ARNI + BB + MRA had better survival during follow-up compared to any other drug combination (log-rank p=0.027). A high rate of ACEI/ARB/ARNI and BB use was observed.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40755965", "sentence_id": "med:pmid:40755965:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40835081", "sentence_id": "med:pmid:40835081:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The use of guideline-directed medical therapy at discharge was suboptimal in both groups, but even lower in Chagas patients, particularly for beta-blockers (52% vs 64%, p = 0.02) and ACEi/ARB/ARNi (54% vs 68%, p = 0.01).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40839760", "sentence_id": "med:pmid:40839760:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Changes in LSS severity at 8 months were analysed using ordinal logistic regression models to estimate the effect of sacubitril/valsartan vs. enalapril or valsartan.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40849246", "sentence_id": "med:pmid:40849246:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40849246", "sentence_id": "med:pmid:40849246:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost-utility ratio below \u20ac20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:conclusion:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "During the 1-year follow-up, patients with MEE over 178\u2005kcal/min were associated with increased risk of all-cause death compared with those with MEE below 178\u2005kcal/min. ARNI significantly reduced MEE compared with ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "According to the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/ARNI, the 210 patients were divided into the ARNI group (107 cases, 51.0%) and the non-ARNI (ACEI/ARB) group (103 cases, 49.0%).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The main outcome measures were the changes in myocardial energy expenditure (MEE) and prognostic indicators after 1-year follow-up. ARNI significantly reduced MEE after 1 year compared with the ACEI/ARB [(129.61\u2009\u00b1\u200940.81)\u2005kcal/min vs. (154.49\u2009\u00b1\u200947.58)\u2005kcal/min, <i>P</i>\u2009<\u20090.01].", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40908036", "sentence_id": "med:pmid:40908036:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The cornerstone of HFrEF management consists of four key medication classes: ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40916703", "sentence_id": "med:pmid:40916703:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40916703", "sentence_id": "med:pmid:40916703:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Participants were randomized 1:1 to sacubitril/valsartan (97/103\u2009mg bid) or enalapril (10\u2009mg bid).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40916703", "sentence_id": "med:pmid:40916703:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40981086", "sentence_id": "med:pmid:40981086:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "While most physicians (66%) knew the target doses for Sacubitril/Valsartan, 83% of them were unaware that the clinical benefit of sacubitril/valsartan at doses below 50% of the target compared to ACE inhibitors remains uncertain and is not well supported by current evidence.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:40981086", "sentence_id": "med:pmid:40981086:sec:abstract:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This finding raises questions about the clinical and economic value of initiating sacubitril/valsartan without subsequent dose optimization, especially given the uncertainty surrounding the efficacy of suboptimal dosing compared to ACE inhibitors.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor-neprilysin inhibitor (ARNI) has a well-established advantage over angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction, the advantage of ARNI has not been clearly proven.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Regardless of the significant improvement in the baseline LVEF observed in patients receiving both ACEI/ARB and ARNI at the 6-week follow-up, the absolute and relative increases in the LVEF were higher in subjects treated with ACEI/ARB.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The efficacy of ARNI is compared with that of ACEI/ARB therapy in patients with their first AMI in terms of improvement of post-infarction LV systolic function.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study population was categorized into pts receiving ARNI and ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:conclusion:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI therapy also significantly reduced MACEs risk (HR\u00a0=\u00a00.392, 95\u00a0% CI: 0.194-0.791, P\u00a0=\u00a00.009). Compared with ACEI/ARB, ARNI demonstrated enhanced preservation of cardiac function, attenuation of adverse ventricular remodeling, and maintenance of ventricular geometry following myocardial infarction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To compare the effects of early angiotensin receptor-neprilysin inhibitor (ARNI) versus angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy on left ventricular remodeling and heart failure progression in patients with acute anterior wall myocardial infarction.<h4>Methods</h4>Patients were stratified by treatment into ARNI (n\u00a0=\u00a097) and ACEI/ARB (n\u00a0=\u00a071) groups.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:results:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Baseline characteristics, cardiac ultrasound data (baseline, 0-3 months, 6-12 months), and major adverse cardiac events (MACEs) were analyzed. The ARNI group demonstrated significantly greater improvements in left ventricular end-diastolic diameter and relative wall thickness versus the ACEI/ARB group.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41049960", "sentence_id": "med:pmid:41049960:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) includes a combination of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/angiotensin receptor neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor agonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41049960", "sentence_id": "med:pmid:41049960:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Increasing age was linked to lower odds of ACEI/ARB/ARNI use, while higher systolic blood pressure (SBP) favored treatment.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "LBBP combined with sacubitril/valsartan is more effective in treating elderly CHD with CHF than LBBP combined with enalapril.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study compares the efficacy and safety of LBBP combined with sacubitril/valsartan and LBBP combined with enalapril in treating elderly coronary heart disease (CHD) patients with chronic heart failure (CHF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Based on the postoperative treatment regimen, patients were divided into the LBBP & sacubitril/valsartan and the LBBP & enalapril groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of them, 53 patients comprised the LBBP & sacubitril/valsartan group and 58 patients comprised the LBBP & enalapril group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After treatment, levels of LVEDd, LVEF, NT proBNP, sSt2 and MMP-9 in the LBBP & sacubitril/valsartan group were significantly improved compared to those in the LBBP & enalapril group (all P<0.05).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The efficacy and safety of left bundle branch pacing combined with sacubitril/valsartan or enalapril in the treatment of elderly coronary heart disease with chronic heart failure.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41079061", "sentence_id": "med:pmid:41079061:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Other comparisons of price affordability were made against the mean daily salary of managers, professional and non-professional workers in the country. The most expensive medication regime for HF in Venezuela was ARNI-based GDMT with a median monthly cost of 393.81USD, followed by ARB-based GDMT and ACEi-based GDMT costing $100.88USD and $82.23USD respectively.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Subgroup analyses demonstrated consistent benefits across all prespecified strata. Early sacubitril/valsartan use was associated with reduced 1-year AF risk vs. ACEI/ARB in AMI complicated by MR, suggesting a potential role in this population; prospective trials are needed to confirm causality.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.744624+00:00"}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Evidence remains limited regarding whether early administration of sacubitril/valsartan confers additional protection against new-onset AF in this high-risk population to traditional ACEI/ARB therapy. To evaluate the impact of early sacubitril/valsartan therapy on the 1-year cumulative incidence of AF in patients with AMI complicated by MR.<h4>Methods</h4>In this single-center retrospective cohort, 1,065 in-patients with AMI complicated by MR (June 2021-December 2023) were categorized by discharge prescription into the Sacubitril/Valsartan group (<i>n</i>\u2009=\u2009427) or the ACEI/ARB group (<i>n</i>\u2009=\u2009638).The primary endpoint was new-onset AF within 1 year.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prespecified subgroup analyses were performed to assess treatment-effect consistency. Despite a higher baseline risk profile in the Sacubitril/Valsartan group, the 1-year cumulative incidence of AF was lower than in the ACEI/ARB group (CIF 10.8% vs. 17.9%; Gray's test <i>P</i>\u2009=\u20090.002).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41080832", "sentence_id": "med:pmid:41080832:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Six secondary endpoints, including dose conversion from ACEi or ARB to ARNI therapy, were assessed.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41084891", "sentence_id": "med:pmid:41084891:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, only 64 patients (22.3%) attained the 4\u2011pillar GDMT of SGLT2i, ARNI/ACEI/ARB, \u03b2\u2011blockers, and MRA at doses equal to or above 50% of the target dose. In the Polish multicenter HEROES registry, over 80% of the patients with HFrEF were\u00a0discharged on 4\u2011pillar GDMT.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "For non-pharmacologic management, referral to HF specialty was made in 30% and cardiac rehabilitation in 22.2%. Among patients with HFrEF seen at the outpatient, there is good physician adherence to betablockers, ACEI/ARNI/ARBs, and diuretics.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Overall, adherence to prescription of beta-blockers (94.8%), ACEI/ARNI/ARBs (88.5%), and diuretics (100%) were high.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Over three months of follow-up, improvement in the quality of care was demonstrated with ACEI/ARNI/ARBs (81.8% to 90.9%), MRA (68.7 to 81.2%), and SGLT2i (58% to 67.7%).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41151613", "sentence_id": "med:pmid:41151613:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Since 2021, evidence\u2011based management of heart failure with reduced ejection fraction (HFrEF) has centred on four pharmacological \"pillars\":\u202f\u03b2\u2011blockers, sacubitril/valsartan (or an ACE inhibitor), mineralocorticoid\u2011receptor antagonists, and sodium-glucose co\u2011transporter\u20112 (SGLT\u20112) inhibitors.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sensitivity analyses excluding one study showed significant improvements in ACEi/ARB/ARNI prescriptions (OR: 1.36, [95% CI: 1.10, 1.69]).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Subgroup analyses showed significant improvements in ACEi/ARB/ARNI (OR:1.35, [95% CI: 1.03, 1.77)]) and beta-blockers (OR:1.48, [95% CI: 1.31, 1.68)]) prescriptions along with reduced total mortality (OR: 0.86, [95% CI: 0.76, 0.98]) in hospitals.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In another subgroup analyses, shorter follow-up periods were associated with improvement in ACEi/ARB/ARNI (OR:1.38, [95% CI: 1.08, 1.77]), beta-blockers (OR: 1.45, [95% CI: 1.28, 1.61]) prescriptions and total mortality (OR: 0.86, [95% CI: 0.75, 0.99]).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41284794", "sentence_id": "med:pmid:41284794:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The last NICE guidelines in 2018 proposed as a second stage one or more of the following interventions delivered by a specialist: angiotensin receptor/neprilysin antagonist (ARNI) instead of ACE inhibitor, ivabradine if in sinus rhythm with a heart rate >70 bpm, a combined hydralazine and nitrate if the patient is of Afro-Caribbean origin, and/or digoxin.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41287294", "sentence_id": "med:pmid:41287294:sec:abstract:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "No significant between-group differences were observed in drug utilization rate of \u03b2-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all <i>P</i>>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41287294", "sentence_id": "med:pmid:41287294:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Multivariate logistic regression was used to identify factors influencing target dose achievement rate for \u03b2-blockers and ACEI/ARB/ARNI therapies in CHF patients.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:conclusion:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients with a number of neurohormonal drugs either unchanged or increased had a lower risk of mortality (odds ratio 0.71, 95% confidence interval 0.53-0.95, P\u200a=\u200a0.023). ATTRwt-CA patients on beta-blockers or ACEi/ARB/ARNI at diagnosis did not have a shorter survival.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:conclusion:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Beta-blockers were discontinued less often than were ACEi/ARB/ARNI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At diagnosis, 60% of patients were on beta-blockers, 58% on ACEi/ARB/ARNI, and 35% on MRA.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients on beta-blockers had more often NYHA class III/IV, a greater burden of comorbidities, and lower LVEF, and those on ACEi/ARB/ARNI had more comorbidities.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Nonetheless, the survival of patients on beta-blockers or ACEi/ARB/ARNI was not significantly shorter over a 2.5-year follow-up (1.6-3.8) (P\u200a=\u200a0.577 and P\u200a=\u200a0.977, respectively), and patients on both drugs did not have a worse outcome than those not receiving any neurohormonal drug (P\u200a=\u200a0.575).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41303015", "sentence_id": "med:pmid:41303015:sec:introduction:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, only 38 (22.0%) patients reached the level of treatment corresponding to \"SGLT2i and ARNI/ACEI/ARB and betablocker and MRA in doses \u2265 50%\".", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41303015", "sentence_id": "med:pmid:41303015:sec:introduction:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the analysis for the whole group (regardless of ejection fraction [EF]), ARNI (angiotensin receptor-neprilysin inhibitor)/ACEI (angiotensin-converting enzyme inhibitor)/ARB (angiotensin receptor blocker) use increased from 63.3% of the subjects at admission to 81.3% at discharge, beta-blocker use increased from 70.6% to 92.6%, MRA (mineralocorticoid receptor antagonist) use increased from 43.1% to 75.8%, and SGLT2i (sodium-glucose co-transporter 2 inhibitor) use increased from 30.1% to 75.0%.", "sentiment_label": "POS", "sentiment_score": 4.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or enalapril (target dose, 10 mg twice daily), in addition to standard therapy.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (-54.3% to -0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (-31.9% to 37.5%) decrease (7.2% wins).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The resulting stratified win ratio was 1.52 (95% CI, 1.28-1.82; P\u2009<\u2009.001) for sacubitril/valsartan compared with enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41377094", "sentence_id": "med:pmid:41377094:sec:introduction:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In multivariable regression analysis, older age was the only independent socio-demographic predictor of under-prescription both overall and for ACEi/ARB/ARNI (OR0.70; 95% CI 0.55-0.89), beta-blockers (OR0.59; 95% CI 0.41-0.84) and SGLT2i (OR0.66, 95% CI 0.47-0.93), while also associated with a loop diuretics use (OR1.56; 95% CI 1.13-2.17).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41408894", "sentence_id": "med:pmid:41408894:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the HFpEF group, 76% were on beta-blockers, 49% on ACEi/ARB, 18% on ARNI, 49% on MRA and 40% on SGLT2i.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41501364", "sentence_id": "med:pmid:41501364:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In a large-scale randomized controlled study of heart failure (HF), angiotensin receptor-neprilysin inhibitors (ARNI) reduced cardiovascular events compared to enalapril, but resulted in more symptomatic hypotension.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41501364", "sentence_id": "med:pmid:41501364:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among 166 patients treated with newly prescribed renin-angiotensin system inhibitor (75.7\u2009\u00b1\u200913.4 years, 57.2% men, and ejection fraction 39\u2009\u00b1\u200917%), 114 were treated with newly prescribed ARNI (ARNI group) and 52 were treated with newly prescribed angiotensin converting enzyme inhibitors or angiotensin receptor blockers but without ARNI (ACEi/ARB group).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41501364", "sentence_id": "med:pmid:41501364:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The initial day of prescription was day 4 [2-6] for the ARNI group and day 3 [1-6] for the ACEi/ARB group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "med:pmid:41501364", "sentence_id": "med:pmid:41501364:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Early changes in BP after ARNI initiation were comparable with those in the ACEi/ARB group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.1101/2025.03.12.25323680", "sentence_id": "ppr:doi:10.1101/2025.03.12.25323680:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The combinations which resulted in the greatest improvement of quality of life were ARNi + BB + MRA + SGLT2i [MD 7.11 (95% CI -0.99-15.22)], which did not have a statistically significant effect, followed by ARNi + BB + SGLT2i [MD 5.33 (95% CI 0.40-10.25)], ACEi + BB + MRA+ SGLT2i [MD 5.32 (95% CI -2.63-13.26)], ACEi + BB + MRA + ivabradine [MD 5.24 (95% CI -3.07-13.55)].", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Regardless of significant improvement of baseline LVEF observed in patients receiving both ACEI/ARB and ARNI in 6 week follow-up the value of absolute and relative LVEF increase were higher in subjects treated with ACEI/ARB.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To com-pare of the efficacy of ARNI versus ACEI/ARB therapy in patients with the first AMI in terms of improvement of post-infarction LV systolic function.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study population was catego-rized into pts receiving ARNI and ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Median \u0394LVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), p=0.018].", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Similarly median relative \u0394LVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), p=0.047].", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In 6-week follow-up in both subgroups a significant improvement in the median LVEF values was achieved: from median LVEF value 30% (27.3; 38) up to 37% (30; 43; p=0.0008) in ARNI and from median LVEF value 36% (33; 39) up to 45% (42; 52; p&amp;lt;0.0001) in ACEI/ARB subgroup.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
{"doc_id": "ppr:doi:10.21203/rs.3.rs-6768681/v1", "sentence_id": "ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "While therapy with beta blockers and ACEI/ARB/ARNI was common within the cohort, only a third of the cohort was treated with SGLT2 inhibitors or mineralocorticoid receptor antagonists.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T12:24:15.760319+00:00"}
